These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Turner BJ; Laine C; Lin YT; Lynch K Arch Intern Med; 2005 Aug 8-22; 165(15):1769-76. PubMed ID: 16087826 [TBL] [Abstract][Full Text] [Related]
24. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Strain EC; Walsh SL; Bigelow GE Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344 [TBL] [Abstract][Full Text] [Related]
25. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence. Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113 [No Abstract] [Full Text] [Related]
26. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Marsch LA; Stephens MA; Mudric T; Strain EC; Bigelow GE; Johnson RE Exp Clin Psychopharmacol; 2005 Nov; 13(4):293-302. PubMed ID: 16366759 [TBL] [Abstract][Full Text] [Related]
27. Buprenorphine: a potential new treatment option for opioid dependence. Srivastava A; Kahan M CMAJ; 2006 Jun; 174(13):1835. PubMed ID: 16785455 [No Abstract] [Full Text] [Related]
28. The diverse clinical uses of opioid receptor drugs. Howland RH J Psychosoc Nurs Ment Health Serv; 2010 May; 48(5):11-4. PubMed ID: 20415289 [TBL] [Abstract][Full Text] [Related]
29. Pharmacogenetic treatments for drug addiction: alcohol and opiates. Haile CN; Kosten TA; Kosten TR Am J Drug Alcohol Abuse; 2008; 34(4):355-81. PubMed ID: 18584566 [TBL] [Abstract][Full Text] [Related]
30. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection. Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797 [TBL] [Abstract][Full Text] [Related]
31. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539 [TBL] [Abstract][Full Text] [Related]
32. Use and misuse of opioid replacement therapies: a Queensland study. Smirnov A; Kemp R Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993 [TBL] [Abstract][Full Text] [Related]
33. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. McCance-Katz EF; Moody DE; Smith PF; Morse GD; Friedland G; Pade P; Baker J; Alvanzo A; Jatlow P; Rainey PM Clin Infect Dis; 2006 Dec; 43 Suppl 4():S235-46. PubMed ID: 17109310 [TBL] [Abstract][Full Text] [Related]
35. The disparate treatment of medications and opiate pain medications under the law: permitting the proliferation of opiates and limiting access to treatment. Ferrara MM Seton Hall Law Rev; 2012; 42(2):741-67. PubMed ID: 22708140 [No Abstract] [Full Text] [Related]
36. Opioid dependence - management in general practice. Frei M Aust Fam Physician; 2010 Aug; 39(8):548-52. PubMed ID: 20877747 [TBL] [Abstract][Full Text] [Related]
37. Outpatient opioid addiction treatment using buprenorphine. Roberson CM Ala Nurse; 2010; 37(2):13-6; quiz 17. PubMed ID: 20666206 [No Abstract] [Full Text] [Related]
38. Buprenorphine: effective treatment of opioid addiction starts in the office. Fiellin DA Am Fam Physician; 2006 May; 73(9):1513-4. PubMed ID: 16719242 [No Abstract] [Full Text] [Related]
39. Treating opioid dependency and coexistent chronic nonmalignant pain. Blondell RD; Ashrafioun L Am Fam Physician; 2008 Nov; 78(10):1132-3. PubMed ID: 19035061 [No Abstract] [Full Text] [Related]
40. Role of buprenorphine in the management of heroin addiction. Sung S; Conry JM Ann Pharmacother; 2006 Mar; 40(3):501-5. PubMed ID: 16434562 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]